
Mineralys emerges with a new take on an old idea for the treatment of hypertension and $40M to play with
Aldosterone, a hormone linked to increased blood pressure, has long been a target of interest for the treatment of hypertension, but selectivity has been a challenge. Now a new company has emerged from stealth to improve where others have failed.
Mineralys Therapeutics uncloaked early Monday morning with $40 million in Series A funds to prep their lead candidate — a selective aldosterone synthase inhibitor licensed from Japan’s Mitsubishi Tanabe — for a pivotal study. The company was launched by Catalys Pacific, the VC firm founder BT Slingsby put together to create new biotechs around Japanese innovation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.